Search results for "liver transplantation."

showing 10 items of 354 documents

ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients

2017

International audience; The advent of safe and highly effective direct-acting antiviral agents (DAAs) has had huge implications for the hepatitis C virus (HCV) transplant field, and changed our management of both patients on the waiting list and those with HCV graft re-infection after liver transplantation (LT). When treating HCV infection before LT, HCV re-infection of the graft can be prevented in nearly all patients. In addition, some candidates show a remarkable clinical improvement and may be delisted. Alternatively, HCV infection can be treated post-LT either soon after the transplant, taking advantage of the removal of the infected native liver, or at the time of disease recurrence, …

Hepatitis C chronicDrugmedicine.medical_specialtyConsensusAntiviral agentmedicine.medical_treatmentHepatitis C virusmedia_common.quotation_subjectWaiting listDiseaseGuidelineLiver transplantationGuidelinesmedicine.disease_cause03 medical and health sciences0302 clinical medicineMED/12 - GASTROENTEROLOGIAMedicineHumansDrug InteractionsIntensive care medicinemedia_commonLiver transplant candidateLiver transplantationHepatologybusiness.industryWaiting listsLiver failure[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyRecurrent hepatitis CDirect Antiviral AgentHepatitis C3. Good healthSurgerychronicAntiviral agentsWaiting list030220 oncology & carcinogenesisInterferon030211 gastroenterology & hepatologyLiver transplant recipientInterferonsbusinessComplication
researchProduct

Autoimmune Lebererkrankungen: Diagnostik und Therapie

2004

Autoimmune Hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and overlap syndromes of these three disease entities are regarded as autoimmune liver diseases. These conditions are important differential diagnoses of elevated liver function tests as about 10 % of liver transplantations in Europe and North America are for these indications. The diagnosis is often difficult but can be facilitated by sequential measurement of relevant autoantibodies, exclusion of other liver disease, ultrasound, ERCP and liver histology. In AIH immunosuppressive therapy has been shown to prevent or stop the development of cirrhosis and improve the prognosis of the patients de…

Hepatitismedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentGastroenterologyAutoimmune hepatitisLiver transplantationmedicine.diseaseGastroenterologydigestive system diseasesPrimary sclerosing cholangitisLiver diseasePrimary biliary cirrhosisInternal medicineImmunologyMedicinebusinessLiver function testsZeitschrift für Gastroenterologie
researchProduct

Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH)

2018

Hepatitismedicine.medical_specialtyHepatologybusiness.industrymedicine.medical_treatmentGastroenterologySalvage therapyHepatitis CHepatitis BLiver transplantationmedicine.diseaseGastroenterology03 medical and health sciences0302 clinical medicinePharmacotherapy030220 oncology & carcinogenesisInternal medicinemedicineCoinfection030211 gastroenterology & hepatologybusinessGastroenterología y Hepatología
researchProduct

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Hepatocellular carcinomaLCmedicine.medical_treatment:diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]NursesRC799-869Liver transplantationCholangiocarcinomaClinical trialsENS-CCAInterquartile rangeDecisió Presa dePandemic:Other subheadings::/diagnosis [Other subheadings]:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]CERO-19Pandèmia de COVID-19 2020-Immunology and AllergyiCCA intrahepatic cholangiocarcinomaCOVID-19 coronavirus disease 2019Liver Cancer Outcome in the COVID-19-pandemic ProjectSettore MED/12 - Gastroenterologiaddc:617IQRGastroenterologyBCLC Barcelona Clinic Liver Cancer:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas [ENFERMEDADES]Diseases of the digestive system. GastroenterologyManagementClinical PracticeClinical trialEuropean Network for the Study of Cholangiocarcinoma:Diagnosis::Clinical Decision-Making [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Fetge - Malalties - DiagnòsticInterquartile rangeLiver cancerLiver cancerPROGRESSION-FREE SURVIVALLiver Cancermedicine.medical_specialtyCoronavirus disease 2019 (COVID-19):Otros calificadores::/diagnóstico [Otros calificadores]610 Medicine & health:Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [DISEASES]LT liver transplantationArticleBarcelona Clinic Liver CancerInternal MedicinemedicineENS-CCA European Network for the Study of CholangiocarcinomaHepatologybusiness.industryCERO-19 Liver Cancer Outcome in the COVID-19-pandemic ProjectCOVID-19IQR Interquartile rangemedicine.diseaseBCLCClinical trialEmergency medicineObservational study610 Medizin und GesundheitbusinessHCC hepatocellular carcinomaLC liver cancerSARS-CoV-2 severe acute respiratory syndrome coronavirus-2
researchProduct

IMPACT OF DIRECT-ACTING ANTIVIRAL THERAPY ON THE NEED FOR LIVER TRANSPLANTATION RELATED TO HEPATITIS C IN GERMANY

2018

Hepatologybiologybusiness.industryHepacivirusmedicine.medical_treatmentMedizinAntiviral therapyHepacivirusHepatitis CHepatitis C ChronicLiver transplantationbiology.organism_classificationmedicine.diseaseAntiviral AgentsLiver Transplantation03 medical and health sciences0302 clinical medicineGermany030220 oncology & carcinogenesisImmunologymedicineHumans030211 gastroenterology & hepatologybusinessDirect acting
researchProduct

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper fr…

2014

Item does not contain fulltext AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity of genetic defects and clinical phenotype of HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance for the recognition and management of HoFH. METHODS AND RESULTS: Early diagn…

Homozygous Familial HypercholesterolemiaSettore MED/09 - Medicina InternaVascular damage Radboud Institute for Health Sciences [Radboudumc 16]MipomersenLipoprotein apheresisGene FrequencyDiagnosisconsensuMedicineChildPhenotypic heterogeneityCiències de la salutAnticholesteremic AgentsHomozygoteCiencias de la saludPedigree3. Good healthEuropePhenotypeCardiovascular DiseasesPractice Guidelines as TopicBlood Component Removallipids (amino acids peptides and proteins)HipercolesterolèmiaHIPERCOLESTEROLEMIA (DIAGNÓSTICO)Cardiology and Cardiovascular MedicineLipoprotein apheresismedicine.medical_specialtyConsensusClinical UpdateEvinacumabReviewsguide line1102 Cardiovascular Medicine And Haematology1016-5169Diagnosis DifferentialHyperlipoproteinemia Type IIGenetic HeterogeneityArcus SenilisHomozygous familial hypercholesterolaemiaGeneticsXanthomatosisHumansGynecologybusiness.industryStatinsHealth sciencesCholesterol LDLAtherosclerosisEzetimibeLomitapideLiver TransplantationEarly DiagnosisCardiovascular System & HematologyHomozygous familial hypercholesterolaemia; consensus; guide lineMutationEuropean atherosclerosis societybusinessAterosclerosiEuropean Heart Journal
researchProduct

2020

Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in liver transplant recipients, but their toxicity needs to be balanced against the benefits. The choice of prevention strategy (prophylaxis or preemptive treatment) depends on the donor/recipient sero-status but may vary between institutions. We conducted a series of consultations and roundtable discussions with German liver transplant center representatives. Based on 20 out of 22 centers, we herein summarize the current approaches to CMV prevention and treatment in the context of liver transplantation in Germany. In 90…

Human cytomegalovirusGanciclovirmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentvirus diseasesValganciclovirContext (language use)ImmunosuppressionViremiaGeneral Medicine030230 surgeryLiver transplantationmedicine.disease3. Good health03 medical and health sciences0302 clinical medicineCurrent practiceInternal medicinemedicine030211 gastroenterology & hepatologybusinessmedicine.drugJournal of Clinical Medicine
researchProduct

Comparative analysis of in situ versus ex situ perfusion on micro circulation in liver procurement--an experimental trial in a porcine model.

2012

The Achilles heel of liver transplantation remains the biliary system. The crucial step for liver preservation is effective rinsing and perfusion of the peribiliary plexus (PBP). Due to the physiology of the vascular tree, it seems almost impossible to achieve the necessary physiologic ranges of pressure and flow by the in situ perfusion technique. We investigated the role of additional ex situ perfusion via the hepatic artery in this animal model.Fifteen German Landrace pigs underwent standardized multiorgan procurement. In situ perfusion and additional ex situ perfusion were performed consecutively. Meanwhile the external pressure applied to the perfusion system was increased stepwise. To…

In situPathologymedicine.medical_specialtyTissue and Organ ProcurementSwinemedicine.medical_treatmentLiver transplantationMicrocirculationAnimal modelHepatic ArteryMedicineAnimalsLiver preservationTransplantationFrozen section procedurebusiness.industryMicrocirculationLiver TransplantationPerfusionmedicine.anatomical_structureModels AnimalSurgeryNuclear medicinebusinessPerfusionArteryTransplantation proceedings
researchProduct

Comparison of two different techniques of reperfusion in adult orthotopic liver transplantation

2006

: The aim of this study was to determine the impact of two reperfusion techniques on the peri-operative hemodynamic changes and early post-operative graft function of adult patients undergoing orthotopic liver transplantation. Material and methods: From June 2003 to May 2004, 50 consecutive liver transplants were performed and divided into two groups: group A, 25 patients, portal vein flush with 500 cm3 of Ringer's lactate without vena caval venting. Group B, 25 patients, vena caval venting with no portal vein flush. Donor and recipient characteristics were similar in both groups. Sixty-four different parameters were analyzed, and Pearson's χ2 test and t-test were used for statistical analy…

InferiorAdultMalemedicine.medical_specialtyOrthotopic liver transplantation; Post-reperfusion syndrome; Reperfusion technique; Adolescent; Adult; Aged; Aged 80 and over; Child; Female; Humans; Liver Transplantation; Male; Middle Aged; Portal Vein; Reperfusion; Tissue Donors; Vena Cava Inferior; TransplantationVena CavaAdolescentOrthotopic liver transplantationmedicine.medical_treatmentPortal veinHemodynamicsPost-reperfusion syndromeVena Cava InferiorLiver transplantationVena caval80 and overmedicineHumansStatistical analysisChildAgedAged 80 and overReperfusion techniqueTransplantationAdult patientsPortal Veinbusiness.industrySignificant differenceMiddle AgedSettore ING-IND/35 - Ingegneria Economico-GestionaleTissue DonorsLiver TransplantationSurgerySettore MED/18 - Chirurgia GeneraleReperfusioncardiovascular systemFemaleOrthotopic liver transplantationbusinessClinical Transplantation
researchProduct

ERAS Protocol for Perioperative Care of Patients Treated with Laparoscopic Nonanatomic Liver Resection for Hepatocellular Carcinoma: The ISMETT Exper…

2020

Background: Liver resection (LR) remains the best therapeutic option for patients with early-stage hepatocellular carcinoma (HCC) with preserved hepatic function and who are not eligible for liver transplantation. After its inception, the enhanced recovery after surgery (ERAS) protocol was widely used for treating patients with liver cancer, although there are still no clear indications for improving upon it in both open and laparoscopic surgery. Objective: This study aims to describe our institute's experience in the application of the ERAS protocol in a cohort of HCC patients, and to explore possible factors that could have an impact on postoperative outcomes. Materials and Methods: We re…

Laparoscopic surgeryLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantation03 medical and health sciences0302 clinical medicinePostoperative ComplicationsmedicineHepatectomyHumansERASPostoperative PeriodAgedRetrospective StudiesAnalgesicsbusiness.industryNutritional SupportLiver NeoplasmsRetrospective cohort studyPerioperativehepatocellular carcinomalaparoscopic liver resectionLength of StayMiddle Agedmedicine.diseaseSurgery030220 oncology & carcinogenesisHepatocellular carcinomaoutcome030211 gastroenterology & hepatologySurgeryFemaleLaparoscopyHepatectomybusinessLiver cancerEnhanced Recovery After Surgery
researchProduct